

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**The effect of bovine colostrum supplementation  
on levels of secretory immunoglobulin-A (S-IgA)  
in saliva of elite athletes, non-exercising controls  
and non-exercising older adults**

A project completed as fulfilment of the  
requirements of a doctoral thesis in clinical nutrition

Massey University  
Albany Campus  
New Zealand

**Christine Crooks  
2007**

## Abstract

Secretory immunoglobulin-A (S-IgA) in saliva may reflect levels of immune defence at other mucosal sites. Reduced levels of salivary S-IgA have been associated with an increased risk for upper respiratory symptoms (URS) in athletes. Previously, the consumption of a nutrition supplement, bovine colostrum (BC) by distance runners, was shown to significantly increase levels of salivary S-IgA compared to baseline; however the mechanism was not known. The immunomodulatory effect of BC is investigated further in these current studies.

Twenty-five swimmers (12 males [M], 13 females [F], age 14-23 years) training at an elite level, 28 lightly-exercising students (9M, 19F, age 18-27 years), and 45 healthy older adults (20M, 20F, age 65-76 years), consumed a supplement of either BC or placebo for ten weeks. Saliva samples were collected at baseline, weekly for four weeks during supplementation and post-supplementation. Blood samples were collected at baseline, monthly during supplementation and post-supplementation.

No significant changes were seen in levels of S-IgA in either BC or placebo groups within any of the cohorts. There was a trend towards a significant difference in URS reportage between BC and placebo groups in the swimmers cohort, but not in the students or older adults. There was also a trend towards a difference in the number of swimmers reporting URS. Fewer numbers of swimmers consuming BC reported URS compared the placebo ( $P=0.062$ ) after consuming BC for four weeks compared to those consuming the placebo. Post-exercise plasma cortisol results were significantly reduced in the BC subgroup compared to the placebo ( $P=0.004$ ).

These results do not support the findings of previous intervention studies investigating the immunomodulatory effect of BC in athletes. However the reduced reportage of URS, among swimmers consuming the BC supplement, suggested there was some benefit to their health. A possible explanation is that BC has impacted on non-infectious causes of URS. Growth factors present in

BC may enhance intestinal repair which could be advantageous to athletes recovering from bouts of prolonged intensive exercise. The effect of gastrointestinal disturbances on local and systemic immunity may be minimised which benefits immune protection. However an inconsistent effect of BC supplementation on immune protection in athletes means further research is still required. In these studies there was no benefit to immune protection in the student or older adult cohort. Further investigation into the safety of BC for all population groups is still required.

# Acknowledgements

To all of the swimmers and students who participated in this study.

To all of the older adults who participated in this study.

To all my supervisors for their guidance and patience, Clare Wall, Frank Cross, Ajmol Ali, Marlena Kruger.

To the swimming club coaches Donna Bouzaid, Jan Cameron, Damien Pedreschi for their permission to include their swimmers in this study.

To Janie Proctor for her assistance with sample collection and collation, dietary data entry and centrifuging of blood samples.

To the research assistants for their support with collecting saliva samples and issuing the trial supplement and study diaries (Janie Proctor, Jane Fenton, Pam von Hurst, Renee Prideaux, Claire Svendsen)

To the research assistants who carried out the dietary interviews and saliva sampling with the older adult cohort (Christel Dunshea-Mooij, Jane Fenton, Cindy Claassens, Catherine Murray, Pam von Hurst).

To Fonterra for funding further bovine colostrum research in particular Donnell Alexander, Elizabeth McMaster and Lynley Drummond for their help in setting up this project.

To Judi Scheffer for her kindness and assistance with statistical analysis.

To ProBus and John Birkbeck for their amazing support during the older adult study.

To the University of Third Age and Gabrielle Graham for their support with the older adult study.

To the Massey Student Health Centre and their assistance with blood collection in particular Vivien Barker and Gabrielle Graham.

To Ajmol Ali for his help to collect samples during the student and swimmer study.

To Phil Pearce (IFNHH, Massey University, PN) for his advice on analytical methods and for carrying out the analysis of plasma and saliva samples.

To Cheryle Dyson, Michele Petrasich, Rohan Ameratunga, Susan Trotman at Lab Plus for their advice on blood collection procedures and advice on cell phenotyping.

To Kay Rowbottom for her endless support in setting up data collection records and arranging printing.

To BOC Gases, in particular Jo, for all her help to get dry ice to me on time for saliva sampling.

To Rachel Sutherland at the Auckland Cancer Society Research Lab and Linley Fray, Institute of Food Nutrition and Human Health, Massey University (PN) for their help and advice with cytokine analyses.

# Introduction

The aim of these current studies was to further investigate the role of a bovine colostrum supplement in mucosal immune protection in other potentially immune depressed groups.

Two studies were planned with three different cohorts (two cohorts in Study 1 and one cohort in Study 2), the sample size for each cohort was based on a power calculation carried out with the results from the previous study involving middle-aged recreational runners [1]. The study design involved saliva and blood sampling as well as the self-recording of wellness symptoms and activity or training, and the monitoring of dietary intake. A large number of saliva samples were provided by the participants at specified sampling times at their training locations from three different Auckland swimming pools, University or home. To ensure standardised sampling procedures were followed research assistants (RAs) were hired to assist with the collection of saliva, aliquotting to microtubes and freezing. Assistance was sought to centrifuge blood, aliquot and freeze the plasma. Further assistance was also sought to issue the trial supplement and collect dietary and anthropometric data. This was especially important during the study with older adults where each participant was visited at their home or place of work.

The planning, co-ordinating and project managing of the two studies was my responsibility which included:

- Development of the research proposal in conjunction with my supervisors
- Preparation of two ethics applications for the different studies
- Recruitment and training of the participants
- Employment and training of the research assistants
- Collection and storage of saliva samples and co-ordination of RAs to assist
- Co-ordination of blood collection with participants, coaches, phlebotomists (Diagnostic Medlab, Massey University Health Centre) and timely delivery of blood samples to LabPlus for analysis

- Co-ordination of blood centrifugation, storage and delivery of plasma samples to the appropriate laboratory for analysis
- Performing cytokine analysis: interleukin (IL)-6, IL-1ra and interferon-alpha at Massey University (Albany campus)
- Issuing of supplement, collection of unconsumed supplement and determining compliance
- Liaison with Fonterra for delivery of supplement and the issuing of ID codes in a double blinded manner
- Liaison with Fonterra for test results of supplement
- Performing dietary interviews, co-ordinating data entry of dietary data and performing quality control of all dietary data
- Checking and 'data-cleaning' all immunological and biochemical data
- Performing statistical analysis of data
- Providing written study summary to participants and updates to ethics committee
- Preparing regular reports for sponsor (with Frank's help)
- Presenting results at conferences which included:
  - Self-reported upper respiratory symptoms were reduced among swimmers who consumed a bovine colostrum supplement, oral presentation, 'New Image'-Colostrum seminar, Rotorua, 2008
  - Reduced reporting of upper respiratory symptoms among swimmers following bovine colostrum supplementation. Oral presentation 'Australian Association of Exercise and Sport Science', conference, September 2006.
  - The effects of ageing on the homing ability of lymphocyte subsets in older adults. Poster presentation to 'Development and Function of Secondary Lymphoid Tissues' conference, Pasteur Institute, Paris, 2006.
  - The Effect of Bovine Colostrum Supplementation on Salivary IgA in Recreational Runners. Poster presentation to 'Nutrigenomics' conference, Auckland, 2006.



- The Effect of Bovine Colostrum Supplementation on Salivary IgA in Distance Runners. Oral presentation to the 'National Sport Science' conference, Kuala Lumpur, 2004.
- Writing thesis

My PhD supervisors provided assistance during the project planning stage and gave support and feedback during the trials and the preparation of the thesis:

- Dr Frank Cross (Frank taught me how to do an enzyme-linked immunoassay and assisted with all report writing)
- Dr Clare Wall (Clare helped with saliva and dietary collection during the older adult study)

In addition:

- Dr Ajmol Ali (Aj helped with the early morning saliva sampling of the swimmers and volunteered as a participant in the student cohort)
- Professor Marlena Kruger supported me through the completion of the thesis, PhD thesis examination and emendations

The research assistants performed the following tasks:

- Janie Proctor (assisted with saliva sampling and blood centrifuging for both Study 1 and 2, performed data entry for most of the wellness and training records for Study 1 and most of the dietary data)
- Christel Dunshea-Mooij (assisted with saliva sampling, anthropometric measurements and diet interviews in Study 2)
- Catherine Murray (assisted with saliva sampling, anthropometric measurements and diet interviews in Study 2)
- Jane Fenton (assisted with saliva sampling, anthropometric measurements and diet interviews in Study 1 and 2, performed most of the data entry of wellness and activity records for Study 2)
- Pam Van Horst (assisted with saliva sampling for Study 1 and 2, anthropometric measurements and diet interviews in Study 2)
- Renee Prideaux (assisted with saliva sampling in Study 1)
- Claire Svendsen (assisted with saliva sampling in Study 1)

- Cindy Claassens (anthropometric measurements and diet interviews in Study 2)

In summary laboratory analysis of samples collected for this study were performed as listed below:

- Blood samples were analysed at LabPlus for full blood count, liver function analysis and cell phenotyping
- Plasma samples were analysed for levels of cytokines by me at the nutrition laboratory, Albany campus, Massey University
- Plasma samples were analysed for immunoglobulins, albumin, cortisol, C-reactive protein and cortisol by Dr Phil Pearce, nutrition laboratory, Palmerston North campus, Massey University
- Saliva samples were analysed for immunoglobulins, albumin and osmolality by Dr Phil Pearce, nutrition laboratory, Palmerston North campus, Massey University

# Table of Contents

	<b>Page</b>
Abstract	i
Acknowledgements	iii
Introduction	v
List of Tables	xvi
List of Figures	xviii
List of Abbreviations used	xx
<b>1.0 Literature Review</b>	<b>1</b>
1.1 Introduction	1
1.2 The mucosal and systemic immune systems	8
1.2.1 Innate immunity	8
1.2.2 Adaptive immunity	9
1.2.3 Immunoglobulins	10
1.3 Protection at the mucosal surface	17
1.3.1 Intestinal mucosal immune system	17
1.3.2 Mucosal protection of the upper respiratory tract	21
1.3.3 Common mucosal immune system (CMIS)	22
1.3.4 Lymphocyte trafficking	23
1.4 Aetiology of upper respiratory tract infections	25
1.5 Effects of exercise on mucosal immunity	28
1.5.1 The effect of exercise-induced stress on immune function	28
1.5.2 The effect of exercise on the gastrointestinal tract	33
1.5.3 The effect of exercise on the induction of stress hormones and their effect on immune function	34
1.5.4 The effect of exercise and the role of growth factors on immune function	36
1.6 The effect of ageing on immune function	37
1.6.1 Respiratory illness in older adults	37
1.6.2 Immune remodelling during senescence	37
1.6.3 Age-related changes to mucosal immunity	40
1.7 The effect of nutrition on mucosal immune protection	42
1.7.1 The effect of carbohydrate status (from dietary intake) on immune protection	45
1.7.2 The effect of carbohydrate supplementation on immune protection before during and after exercise	46
1.7.3 The effect of protein status on immune protection	48
1.7.4 The effect of dietary fat on immune protection	49
1.7.5 The effect of micronutrient intake on mucosal immune function	52
1.7.6 The effect of bovine colostrum on mucosal immunity	61

## Table of Contents continued

	<b>Page</b>	
1.8	Assessment of dietary intake.	76
1.8.1	Dietary assessment methods	76
1.8.2	Precision and controlling for errors	80
1.8.3	Estimating daily energy expenditure	81
1.9	Summary.	83
<b>2.0</b>	<b>Study aims</b>	<b>84</b>
<b>3.0</b>	<b>Methods</b>	<b>86</b>
3.1	Study participants.	88
3.1.1	Study 1	88
3.1.2	Study 2	91
3.2	Supplement used in both intervention studies.	93
3.3	Study design.	95
3.3.1	Study 1	95
3.3.2	Study 2	98
3.4	Assessment of the primary outcome variable: secretory IgA in saliva.	99
3.4.1	Saliva collection	99
3.4.2	Salivary immunoglobulin analysis	99
3.5	Assessment of secondary outcome variables: immunological and biochemical parameters	101
3.6	Investigation into the mechanism by which BC may modulate levels of salivary S-IgA	105
3.7	Training/activity and wellness records	111
3.7.1	Training/activity records	111
3.7.2	Wellness records	114
3.8	Estimation of daily energy expenditure	116
3.9	Assessment of reported dietary intake	117
3.10	Anthropometric measurements	119

## Table of Contents continued

	<b>Page</b>	
3.11	Statistical analysis	121
3.11.1	Investigation of differences in participant characteristics	121
3.11.2	Effect of BC supplement on the main study outcome variables, plasma immunoglobulins and plasma biochemical parameters	122
3.11.3	Investigation into how BC may modulate mucosal immunity (analysis of cytokines, hormones and lymphocyte subsets in the subgroups)	123
3.11.4	Control for dietary intake	124
<b>4.0</b>	<b>Results</b>	<b>125</b>
4.1	Characteristics of the participants	128
4.1.1	Haematological parameters	130
4.2	Main outcome variable.	130
4.2.1	Salivary immunoglobulins	130
4.2.2	Measurement of hydration status	135
4.3	Secondary outcome variables.	137
4.3.1	Plasma immunoglobulins	137
4.3.2	URS reportage	140
4.4	Investigation of the mechanism by which BC supplementation may modulate mucosal immunity	145
4.4.1	Plasma cortisol	145
4.4.2	Plasma cytokines	146
4.4.3	Plasma IGF-1	150
4.4.4	Lymphocyte subsets	150
4.4.5	Associations between baseline levels of plasma IGF-1, %CD8 and the CD4/CD8 ratio in the swimmers subgroup	153
4.4.6	Baseline comparisons between the cohorts for salivary and plasma parameters	153
4.4.4	Baseline comparisons between the cohorts for lymphocyte subsets	154
4.5	Reported daily dietary intake	157
4.5.1	Reported daily energy intake	157
4.5.2	Reported daily macronutrient intake	160
4.5.3	Reported daily micronutrient intake	162

## Table of Contents continued

	<b>Page</b>
<b>5.0 Discussion</b>	<b>166</b>
5.1 Overview	166
5.2 Methodological considerations	166
5.3 Optimising levels of S-IgA in saliva during sample collection	173
5.4 Haematological parameters	176
5.5 The effect of BC supplementation on salivary S-IgA (the main outcome variable)	178
5.6 The effect of BC supplementation on plasma immunoglobulins (secondary outcome variables)	181
5.7 The effect of BC supplementation on URS reportage (secondary study outcome variable)	183
5.7.1 Self-reported URS by the swimmers cohort	183
5.7.2 The effect of the influenza vaccination on URS reportage in the older adult cohort	187
5.8 Plasma cortisol levels in the swimmers subgroup	188
5.9 Lymphocyte subsets	189
5.10 The effect of ageing on the homing ability of lymphocytes	194
5.11 The possible effect of prolonged intensive exercise, on intestinal permeability and the homing ability of lymphocytes	196
5.12 Measurement of dietary intake	198
5.12.1 Estimated daily energy expenditure	199
5.12.2 Comparison of reported dietary intake to the dietary guidelines	202
<b>6.0 Conclusion</b>	<b>206</b>
<b>7.0 Limitations of the study</b>	<b>211</b>
<b>8.0 Recommendations for future research</b>	<b>214</b>
<b>9.0 References</b>	<b>217</b>

## Table of Contents continued

	<b>Page</b>
<b>10.0 Appendices</b>	<b>232</b>
10.1 The effect of bovine colostrum supplementation on salivary IgA in distance runners	233
10.2 Information pamphlet: Study 1 (Swimmers and Students)	252
10.3 Consent form: Study 1 (Swimmers and Students)	255
10.4 Ethics approval letter: Study 1 (Swimmers and Students)	258
10.5 Training and wellness diary: Study 1 (Swimmers)	261
10.6 Food diary: Study 1 (Swimmers and Students)	265
10.7 Training and wellness diary: Study 1 (Students)	269
10.8 Information pamphlet: Study 2 (Older Adults)	273
10.9 Consent form: Study 2 (Older Adults)	276
10.10 Ethics approval letter: Study 2 (Older Adults)	279
10.11 Study 2: Screening questionnaire for Older Adults	282
10.12 Activity and wellness diary: Study 2 (Older Adults)	285
10.13 Diet recall interview questionnaire: Study 2 (Older Adults)	289
10.14 Formulation of bovine colostrum and placebo blends used in supplementation trials	291
10.15 Levels of endogenous bio-actives measured in the bovine colostrum (BC) and placebo blends (supplied by Fonterra)	293
10.16 ELISA method for human IL-6	295
10.17 ELISA method for human IL-1ra	298
10.18 ELISA method for human IFN- $\alpha$	301
10.19 List of metabolic equivalents (METs) for physical activities performed by the participant	303
10.20 Mean weekly activity factor (mean wAF) converted to Physical Activity Level (PAL) by cohort	305

## Table of Contents continued

	<b>Page</b>
10.21 Haematological parameters and liver function enzymes (Older adults)	307
10.22 Salivary immunoglobulins, albumin and osmolality	310
10.23 Individual plots of S-IgA by cohort and gender	313
10.24 Plasma immunoglobulins, albumin and C-reactive protein (CRP)	317
10.25 Subgroup results: plasma cortisol, interleukin-6 (IL-6), interleukin-1 receptor antagonist (IL-1ra) and insulin-like growth factor one (IGF-1)	320
10.26 Subgroup results: Leucocyte and lymphocyte subsets (absolute numbers)	322
10.27 Subgroup results: Lymphocyte subsets (percentages)	325
10.28 Subgroup results: Mean fluorescent intensities (MFIs) for lymphocyte subsets expressing CD49d	328
10.29 Baseline comparison of immunoglobulin and albumin parameters in saliva and plasma	3330
10.30 Subgroup results: baseline comparison between cohorts for absolute numbers of leucocytes and lymphocyte subsets	332
10.31 Subgroup results: baseline comparison between cohorts for percentages of lymphocyte subsets, plasma cytokines, plasma cortisol	334
10.32 Reported daily energy intake (RDEI) and estimated daily energy expenditure (EDEE)	336
10.33 Reported daily macronutrient and fibre intake adjusted for energy differences	338
10.34 Reported daily micronutrient intake adjusted for energy differences	340
10.35 Contribution to daily intake of micronutrients from nutrition supplementation (Students)	344
10.36 Contribution to daily intake of micronutrients from nutrition supplementation (Swimmers)	346
10.37 Contribution to daily intake of micronutrients from nutrition supplementation (Older adults)	349
10.38 Guidelines for dietary intake for athletes in New Zealand	354



## Table of Contents continued

	<b>Page</b>
10.39 Summary of nutrient reference values (NRV) for Australia and New Zealand	356
10.40 Summary of nutrient reference values (NRV) for Australia and New Zealand: Older adults (NHMRC, 2006)	358

## List of Tables

		<b>Page</b>
Table 1	Immune parameters that could be monitored to measure changes to mucosal immunity listed in order of usefulness	4
Table 2	Summary of nutrient deficiencies or excesses that may affect immunity	44
Table 3	Summary of data for macronutrient content of bovine colostrum (BC) and mature bovine milk (MBM)	62
Table 4	Summary of some of the peptide growth factors in bovine BC and MBM with typical levels	64
Table 5	Comparison of IGF-1 in colostrum and mature milk from different species	65
Table 6	Ribonucleotides ( $\mu\text{mol/L}$ ) in bovine milk at different stages postpartum	67
Table 7	Typical concentrations of immunoglobulins (Igs) in BC and MBM	68
Table 8	Characteristics of humoral anti-microbial factors in BC and MBM	69
Table 9	Summary of studies investigating the effect of a BC intervention on mucosal function and immunity	73
Table 10	Predicted number of days of dietary recording required taking into intra-individual variation compared to number of days required for groups of athletes	78
Table 11	Summary of dietary analysis methodologies appropriate for use in a nutrition intervention trial	79
Table 12	Bio-active levels for the BC flavour variants	94
Table 13	Sampling plan for whole blood samples	101
Table 14	Summary of sample collection, storage and analytical procedures for immunological, biochemical and hormonal parameters	103
Table 15	Recombinant standards used for the ELISA analysis of the plasma cytokines IL-6, IL-1ra and IFN- $\alpha$	106
Table 16	Conversion of mean weekly activity factor (wAF) to a physical activity level (PAL) for M and F	116

## List of Tables continued

		<b>Page</b>
Table 17	Descriptive statistics	126
Table 18	Baseline levels for salivary S-IgA, IgG and IgM for each cohort	130
Table 19	Reference ranges for salivary Igs and albumin	130
Table 20	Summary of the results for the salivary/osmolality ratio at baseline and at the end of the supplementation period for each cohort	136
Table 21	Student mean plasma IgA and IgG results (g/L), older adult mean plasma IgA (g/L) results at baseline, after 5 and 10 weeks supplementation and post-supplementation	138
Table 22	Summary data for total URS days reported at baseline and over the supplementation period within each cohort	140
Table 23	Plasma cortisol (nmol/L) levels for the swimmers after four weeks of supplementation (mean $\pm$ SEM)	145
Table 24	Associations between immune parameters and plasma hormones in the swimmers subgroup	153
Table 25	Changes in mean body mass between baseline and week 10 of the supplementation period	159
Table 26	Macronutrient requirements for athletes exercising more than 2 hours per day and 4-7 days per week	160
Table 27	Summary of the reported daily dietary intake of micronutrients that were below the estimated average requirement	163
Table 28	Estimated average requirements for Zinc, Vitamin E and Selenium	163
Table 29	Intensity level (VO <sub>2</sub> max) that exercise is performed at for different sports	186
Table 30	Comparative effects of ageing on the intestinal mucosal immune response in aged rats and with various markers of changes in mucosal immune function measured in older adults in this study	195
Table 31	Differences in RDEI compared to EDEE in an active older male and inactive older female	201
Table 32	Summary of EDEE for the older adult cohort when Harris-Benedict and Schofield equations are used to estimate BMR	203

# List of Figures

		<b>Page</b>
Figure 1	The link between the innate and adaptive immune system	10
Figure 2	Synthesis and transport of S-IgA across the epithelial membrane	12
Figure 3	Mucosal immune system in the GALT	18
Figure 4	M-Cell in the follicular-associated epithelium of Peyer's patches (PPs)	20
Figure 5	Communication between the brain and the immune system in response to exercise-induced stress	35
Figure 6	Summary of the biosynthesis and metabolism of long chain polyunsaturated fatty acids that may have an immunomodulatory effect in humans	50
Figure 7	Study 1 design: Swimmers and students	97
Figure 8	Study 2 design: Older adults	98
Figure 9	Example of flow cytometry analysis for T-cells expressing CD4 and CD49d in blood sampled from an older adult	109
Figure 10	Wellness record completed daily by participant	114
Figure 11	Salivary s IgA levels (mg/L) in the swimmers cohort at baseline (Base), 4 weeks, 8 weeks, 10 weeks of supplementation and post-supplementation (Post)	132
Figure 12	Salivary s IgA levels (mg/L) in the student cohort at baseline (Base), 4 weeks, 8 weeks, 10 weeks of supplementation and post-supplementation (Post)	132
Figure 13	Salivary s IgA levels (mg/L) in the older adult cohort at baseline (Base), 4 weeks, 8 weeks, 10 weeks of supplementation and post-supplementation (Post)	132
Figure 14	Total days of URS reported by the BC and placebo participants in the swimmers cohort in each week	141
Figure 15	Number of swimmers reporting and not reporting URS	142
Figure 16	Total days of mild URS (URS1) reported by the BC and placebo participants in the swimmers cohort in each week	142

## List of Figures continued

	<b>Page</b>
Figure 17 Total days of URS reported by the BC and placebo participants in the student cohort in each week	143
Figure 18 Total days of URS reported by the BC and placebo participants in the older adult cohort in each week	144
Figure 19 Cytokine (IL-6, IL-1ra, IFN- $\alpha$ ) trends (pg/mL) for the swimmers subgroup at baseline (Base), 5 weeks, 10 weeks and post-supplementation (Post) (mean $\pm$ SEM)	147
Figure 20 Cytokine (IL-6, IL-1ra, IFN- $\alpha$ ) trends (pg/mL) for the students subgroup at baseline (Base), 5 weeks, 10 weeks and post-supplementation (Post) (mean $\pm$ SEM)	148
Figure 21 Cytokine (IL-6, IL-1ra, IFN- $\alpha$ ) trends (pg/mL) for the older adult subgroup at baseline (Base), 5 weeks, 10 weeks and post-supplementation (Post) (mean $\pm$ SEM)	149

## List of Abbreviations used

<b>Abbreviation</b>	<b>Definition</b>
AF	Activity factor
Alb	Albumin
APC	Antigen presenting cell
Ave	Average
BALT	Bronchial associated lymphoid tissue
Base	Baseline
BC	Bovine colostrum
B-cell	B-lymphocyte
BM	Body mass
BMR	Basal metabolic rate
CD	Cluster of differentiation number
CHO g/kgBM	Grams of carbohydrate per kilogram of bodymass
CHO/kgBM/day	Carbohydrate per kilogram body mass per day
CMIS	Common mucosal immune system
CTL	Cytotoxic T-cell
diff	Difference
Drink g/day	Grams of drink consumed per day
EDEE	Estimated daily energy expenditure
EGF	Epidermal growth factor
F	Female
GALT	Gut associated lymphoid tissue
Gen	Gender
GH	Growth hormone
IFN	Interferon
IFN- $\alpha$	Interferon-alpha
Ig	Immunoglobulin
IgA	Immunoglobulin A
IGF-1	Insulin-like growth factor-1
IgG	Immunoglobulin G
IgM	Immunoglobulin M
IL	Interleukin
IL-1ra	Interleukin-1receptor antagonist
IL-6	Interleukin-6
Intens	Intensity
IQ range	Interquartile range
J-chain	Polypeptide joining chain
LP	Lamina propria
LPS	Lipopolysaccharide
M	Male
MAdCAM-1	Mucosal addressin cell adhesion molecule
MBM	Mature bovine milk
M-cell	Microfold cell
Med	Median
MET	Metabolic equivalent
MHC	Major histocompatibility complex
N/A	Not applicable
ND	Not detected
No Ana.	Analysis not performed
NP	Not possible to calculate
NRV	Nutrient reference value
NSAID	Non-steroid anti-inflammatory drug
OA	Older adults
Osm	Osmolality
PAL	Physical activity level
PIgR	Receptor for polymeric immunoglobulin
PI	Placebo

## List of Abbreviations used (continued)

<b>Abbreviation</b>	<b>Definition</b>
Post	Post-supplementation
PPs	Peyer's patches
Ptn g/kgBM	Grams of protein per kilogram of body mass
RDBPC	Randomised double blind placebo controlled
RDDI	Reported daily dietary intake
RDEI	Reported daily energy intake
RDI	Reported daily intake
SEM	Standard error of the mean
S-IgA	Secretory immunoglobulin A
St	Students
Sw	Swimmers
T-cell	T-lymphocyte
TGF- $\beta$	Transforming growth factor beta
UL	Upper level of intake
URS	Upper respiratory symptoms
URT	Upper respiratory tract
URTI	Upper respiratory tract infection
VCAM-1	Vascular adhesion molecule
wks	Weeks